RARE – Ultragenyx Pharmaceutical Inc.
RARE — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
10.88
Margin Of Safety %
Put/Call OI Ratio
0.81
EPS Next Q Diff
0.16
EPS Last/This Y
1.43
EPS This/Next Y
4.48
Price
23.17
Target Price
52.45
Analyst Recom
1.29
Performance Q
0.17
Upside
-982.9%
Beta
0.26
Ticker: RARE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | RARE | 22.58 | 0.83 | 0.05 | 19686 |
| 2026-03-10 | RARE | 22.84 | 0.83 | 0.72 | 19698 |
| 2026-03-11 | RARE | 22.21 | 0.83 | 0.17 | 19718 |
| 2026-03-12 | RARE | 21.7 | 0.83 | 0.16 | 19707 |
| 2026-03-13 | RARE | 21.71 | 0.83 | 0.16 | 19707 |
| 2026-03-17 | RARE | 21.59 | 0.83 | 0.17 | 19839 |
| 2026-03-18 | RARE | 20.45 | 0.80 | 429.50 | 19493 |
| 2026-03-19 | RARE | 20.4 | 1.10 | 0.92 | 22771 |
| 2026-03-20 | RARE | 19.89 | 1.04 | 0.70 | 22163 |
| 2026-03-23 | RARE | 20.26 | 1.04 | 0.78 | 17044 |
| 2026-03-24 | RARE | 18.49 | 1.06 | 0.47 | 17191 |
| 2026-03-25 | RARE | 19.85 | 0.77 | 0.06 | 28933 |
| 2026-03-26 | RARE | 20 | 0.77 | 0.18 | 29008 |
| 2026-03-27 | RARE | 19.37 | 0.76 | 0.07 | 29123 |
| 2026-03-30 | RARE | 19.29 | 0.76 | 1.25 | 29121 |
| 2026-03-31 | RARE | 20.94 | 0.76 | 0.03 | 29127 |
| 2026-04-01 | RARE | 21.43 | 0.76 | 1.64 | 29300 |
| 2026-04-02 | RARE | 22.44 | 0.76 | 7.90 | 29341 |
| 2026-04-06 | RARE | 22.88 | 0.81 | 0.58 | 30443 |
| 2026-04-07 | RARE | 23.16 | 0.81 | 0.09 | 30652 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | RARE | 22.59 | 10.2 | - | -4.38 |
| 2026-03-10 | RARE | 22.85 | 10.2 | - | -4.38 |
| 2026-03-11 | RARE | 22.21 | 10.2 | - | -4.38 |
| 2026-03-12 | RARE | 21.69 | 10.2 | - | -4.38 |
| 2026-03-13 | RARE | 21.33 | 10.2 | - | -4.38 |
| 2026-03-17 | RARE | 21.59 | 9.2 | - | -4.40 |
| 2026-03-18 | RARE | 20.44 | 9.2 | - | -4.40 |
| 2026-03-19 | RARE | 20.41 | 9.2 | - | -4.40 |
| 2026-03-20 | RARE | 19.87 | 9.2 | - | -4.40 |
| 2026-03-23 | RARE | 20.27 | 9.2 | - | -4.40 |
| 2026-03-24 | RARE | 18.50 | 9.2 | - | -4.40 |
| 2026-03-25 | RARE | 19.84 | 9.2 | - | -4.40 |
| 2026-03-26 | RARE | 19.98 | 9.2 | - | -4.40 |
| 2026-03-27 | RARE | 19.38 | 9.2 | - | -4.40 |
| 2026-03-30 | RARE | 19.29 | 9.2 | - | -4.40 |
| 2026-03-31 | RARE | 20.93 | 9.2 | - | -4.40 |
| 2026-04-01 | RARE | 21.42 | 9.2 | - | -4.40 |
| 2026-04-02 | RARE | 22.45 | 9.2 | - | -4.40 |
| 2026-04-06 | RARE | 22.87 | 9.2 | - | -4.40 |
| 2026-04-07 | RARE | 23.17 | 9.2 | - | -4.40 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | RARE | -2.23 | -2.94 | 10.80 |
| 2026-03-10 | RARE | -2.40 | -2.94 | 10.80 |
| 2026-03-11 | RARE | -2.40 | -2.94 | 10.51 |
| 2026-03-12 | RARE | -2.40 | -2.94 | 10.51 |
| 2026-03-13 | RARE | -2.35 | -2.94 | 10.51 |
| 2026-03-17 | RARE | -2.35 | -2.83 | 10.51 |
| 2026-03-18 | RARE | -2.35 | -2.83 | 10.51 |
| 2026-03-19 | RARE | -2.35 | -2.83 | 10.51 |
| 2026-03-20 | RARE | -2.35 | -2.83 | 10.51 |
| 2026-03-23 | RARE | -2.35 | -2.83 | 10.51 |
| 2026-03-24 | RARE | -2.35 | -2.83 | 10.51 |
| 2026-03-25 | RARE | -2.35 | -2.83 | 10.88 |
| 2026-03-26 | RARE | -2.35 | -2.83 | 10.88 |
| 2026-03-27 | RARE | -2.35 | -2.83 | 10.88 |
| 2026-03-30 | RARE | -2.35 | -2.87 | 10.88 |
| 2026-03-31 | RARE | -2.35 | -2.87 | 10.88 |
| 2026-04-01 | RARE | -2.35 | -2.87 | 10.88 |
| 2026-04-02 | RARE | -2.35 | -2.87 | 10.88 |
| 2026-04-06 | RARE | -2.43 | -2.95 | 10.88 |
| 2026-04-07 | RARE | -2.43 | -2.95 | 10.88 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.29
Avg. EPS Est. Current Quarter
-1.43
Avg. EPS Est. Next Quarter
-1.13
Insider Transactions
-2.43
Institutional Transactions
-2.95
Beta
0.26
Average Sales Estimate Current Quarter
163
Average Sales Estimate Next Quarter
179
Fair Value
Quality Score
24
Growth Score
48
Sentiment Score
82
Actual DrawDown %
80.7
Max Drawdown 5-Year %
-84
Target Price
52.45
P/E
Forward P/E
PEG
P/S
3.33
P/B
P/Free Cash Flow
EPS
-5.84
Average EPS Est. Cur. Y
-4.4
EPS Next Y. (Est.)
0.08
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-85.54
Relative Volume
0.62
Return on Equity vs Sector %
691.3
Return on Equity vs Industry %
707.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.24
EBIT Estimation
◆
RARE
Healthcare
$23.15
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
59.9
Range 1M
95.3%
Sup Dist
3.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
27.7%
EPS NY
85.7%
52W%
19.4%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-26.6% upside
Upside
-26.6%
Quality
24
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1371
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
RARE
Latest News
—
Caricamento notizie per RARE…
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading